Table 3 Summary of trial characteristics by tumour site
Tumour Type | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Colorectal | Upper gastrointestinal/ hepatobiliary | Urology | Breast | Gynaecological | Head and neck | Lung | Multiple | Skin | ||||||||||
Number (N = 744) | % | Number (N = 174) | % | Number (N = 214) | % | Number (N = 283) | % | Number (N = 399) | % | Number (N = 36) | % | Number (N = 146) | % | Number (N = 111) | % | Number (N = 152) | % | |
Intervention | Endoscopy (242) | 33 | Endoscopy (53) | 30 | Pharmacological (50) | 23 | Health promotion (107) | 38 | Diagnostic test (88) | 22 | Imaging (10) | 28 | Imaging (62) | 42 | Health promotion (50) | 45 | Health promotion (63) | 41 |
Health promotion (206) | 28 | Imaging (40) | 23 | Imaging (42) | 20 | Imaging (74) | 26 | Pharmacological (79) | 20 | Diagnostic test (9) | 25 | Health promotion (24) | 16 | Pharmacological (28) | 25 | Pharmacological (35) | 23 | |
Pharmacological (83) Behaviour change (50) Imaging (43) Molecular test (29) Biomarkers (15) Questionnaire (12) Standard of care (9) | 11 7 6 4 2 2 1 | Diagnostic test (27) Pharmacological (20) Health promotion (14) Biomarker (10) Surgery (5) | 16 12 8 6 3 | Diagnostic test (32) Health promotion (29) Biomarker (14) Standard of care (11) Molecular test (11) Behaviour change (8) Prediction tool (6) | 15 14 7 5 5 4 3 | Pharmacological (41) Behaviour change (30) Lifestyle (8) Diagnostic test (7) Standard of care (4) | 14 11 3 2 1 | Health promotion (79) Molecular test (53) Standard of care (24) Imaging (12) Biomarker (11) Endoscopy (10) Questionnaire (8) Prediction tool (5) | 20 13 6 3 3 3 2 1 | Pharmacological (6) Biomarker (4) Endoscopy (2) Behaviour change (2) | 17 11 6 6 | Pharmacological (17) Behaviour change (10) Biomarker (9) Endoscopy (8) Diagnostic test (7) Questionnaire (4) Risk prediction (2) | 12 7 6 5 5 3 1 | Behaviour change (8) Lifestyle (6) Questionnaire (4) Imaging (4) Diagnostic test (3) Risk prediction (2) | 75 4 4 3 2 | Behaviour change (24) Diagnostic test (9) Imaging (7) Questionnaire (7) Light therapy (3) | 16 6 5 5 2 | |
Geographical area (top 3) | North America (298) | 40 | Asia (70) | 40 | Europe (87) | 41 | North America (138) | 49 | Europe (127) | 32 | Asia (17) | 47 | Europe (62) | 43 | North America (66) | 59 | North America (87) | 57 |
Europe (260) | 35 | Europe (45) | 26 | North America (86) | 40 | Europe (70) | 25 | North America (117) | 29 | Europe (9) | 25 | North America (58) | 40 | Europe (22) | 20 | Europe (34) | 22 | |
Asia (125) | 17 | North America (43) | 25 | Asia (25) | 12 | Asia (26) | 9 | Asia (62) | 16 | North America (8) | 22 | Asia (20) | 14 | Asia (12) | 11 | Australasia (20) | 13 | |
Subtypes within each category (where relevant)* | Biliary (1) | 1 | Bladder (16) | 7 | Cervical (359) | 90 | Head and neck NOS (3) | 8 | ||||||||||
Gastric (35) | 20 | Prostate (194) | 91 | Endometrial (19) | 5 | Laryngeal (1) | 3 | |||||||||||
Liver (40) | 23 | Renal (2) | 1 | Ovarian (19) | 5 | Nasopharyngeal (6) | 17 | |||||||||||
Oesophagus (74) | 42 | Testicular (2) | 1 | Vaginal (2) | 0.5 | Oral (20) | 56 | |||||||||||
Pancreas (24) | 14 | Vulval (1) | 0.3 | Thyroid (6) | 17 | |||||||||||||
Total participants | Range | Range | Range | Range | Range | Range | Range | Range | Range | |||||||||
3- 362,165 | 18- 184,786 | 14- 721,299 | 11- 1,198,493 | 15- 860,028 | 12- 183,000 | 20- 154,901 | 8- 1,555,000 | 4- 360,288 | ||||||||||